Literature DB >> 7067604

The ocular signs and symptoms of myasthenia gravis.

H J Oosterhuis.   

Abstract

Myasthenia gravis is a chronic disease characterized by a fluctuating weakness of voluntary muscles, with a preference for the muscles innervated by the cranial nerves. Ocular symptoms (ptosis, diplopia) were present at onset in 65% of 432 own patients and in 10% of these patients the disease remained confined to the extrinsic eye muscles. A complete remission occurred in 30% of the purely ocular cases within 10 years of onset. The diagnosis depends upon the pattern of weakness, the spontaneous or provoked fluctuation of the symptoms and the favourable response to anticholinesterases. The presence of antibodies against acetylcholine receptor protein is the most recent tool to confirm the diagnosis, but they are absent in 10-20% of the patients with generalized MG and in 20-50% of the purely ocular cases. As the reaction to anticholinesterases in ocular MG is sometimes equivocal or even absent auxillary investigations (electromyography, tonography, nystagmography, curaretest) may be necessary. Oral anticholinesterases (Pyridostigmin, Prostigmin, Ambenomium) usually have a moderate effect on the ptosis and a poor effect on the diplopia so that other measures (ptosishooks, covering one eye) are necessary. In selected patients alternate-day Prednisone is the therapy of choice.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7067604     DOI: 10.1007/bf01675867

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  28 in total

1.  Electromyography; a tool in ocular and neurologic diagnosis. I. Myasthenia gravis.

Authors:  G M BREININ
Journal:  AMA Arch Ophthalmol       Date:  1957-02

2.  Edrophonium infrared optokinetic nystagmography in the diagnosis of myasthenia gravis.

Authors:  R H Spector; R B Daroff
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

3.  Lancaster red-green test in evaluation of edrophonium effect in myasthenia gravis.

Authors:  J A Retzlaff; T P Kearns; F M Howard; M L Cronin
Journal:  Am J Ophthalmol       Date:  1969-01       Impact factor: 5.258

4.  Myasthenia gravis: dynamic changes in saccadic waveform, gain, and velocity.

Authors:  D Schmidt; L F Dell'Osso; L A Abel; R B Daroff
Journal:  Exp Neurol       Date:  1980-05       Impact factor: 5.330

5.  [The significance of oculo-electromyography in the diagnosis of myasthenia].

Authors:  P Marek; A Szobor
Journal:  Nervenarzt       Date:  1966-11       Impact factor: 1.214

6.  [Diagnosis of myasthenic eye signs. Clinical signs and electronystagmographical findings of saccadic eye movements (author's transl)].

Authors:  D Schmidt
Journal:  Klin Monbl Augenheilkd       Date:  1975-11       Impact factor: 0.700

7.  Pupillary dysfunction in myasthenia gravis.

Authors:  F E Lepore; G E Sanborn; J T Slevin
Journal:  Ann Neurol       Date:  1979-07       Impact factor: 10.422

8.  Patterns of acetylcholine receptor antibody fluctuation in myasthenia gravis.

Authors:  M E Seybold; J M Lindstrom
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

9.  Pupillary abnormalities in myasthenia gravis. Report of a case.

Authors:  A G BAPTISTA; H SILVA E SOUZA
Journal:  Neurology       Date:  1961-03       Impact factor: 9.910

10.  Internal 'ophthalmoplegia' in myasthenia gravis.

Authors:  Y Herishanu; S Lavy
Journal:  Ophthalmologica       Date:  1971       Impact factor: 3.250

View more
  11 in total

1.  Concomitant euthyroid Graves' ophthalmopathy and isolated ocular myasthenia gravis.

Authors:  H Raef; M Ladinsky; R Arem
Journal:  Postgrad Med J       Date:  1990-10       Impact factor: 2.401

2.  Eyelid ptosis enhanced after steroid pulse therapy in ocular myasthenia gravis: a case report.

Authors:  Haruo Nishijima; Tatsuya Ueno; Chieko Suzuki; Masayuki Baba; Masahiko Tomiyama
Journal:  Neurol Sci       Date:  2015-01-28       Impact factor: 3.307

3.  Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.

Authors:  M J Kupersmith; G Ying
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

4.  Repertoires of autoantibodies against homologous eye muscle in ocular and generalized myasthenia gravis differ.

Authors:  C W Zimmermann; F Eblen
Journal:  Clin Investig       Date:  1993-06

5.  The contribution of oculography to early diagnosis of myasthenia gravis. A study of saccadic eye movements using the infrared reflection method in 22 cases.

Authors:  C E Sollberger; O Meienberg; H P Ludin
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1986

6.  Long-term outcome and quality of life after open and thoracoscopic thymectomy for myasthenia gravis: analysis of 131 patients.

Authors:  Kai Bachmann; Doreen Burkhardt; Inken Schreiter; Jussuf Kaifi; Christoph Busch; Gunther Thayssen; Jakob R Izbicki; Tim Strate
Journal:  Surg Endosc       Date:  2008-02-23       Impact factor: 4.584

7.  Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up.

Authors:  Mark J Kupersmith
Journal:  J Neurol       Date:  2009-04-18       Impact factor: 4.849

8.  Long-term follow-up of strabismus surgery for patients with ocular myasthenia gravis.

Authors:  Jason H Peragallo; Federico G Velez; Joseph L Demer; Stacy L Pineles
Journal:  J Neuroophthalmol       Date:  2013-03       Impact factor: 3.042

9.  The anti-acetylcholine receptor antibody test in suspected ocular myasthenia gravis.

Authors:  Jung Jin Lee; Kyung Min Koh; Ungsoo Samuel Kim
Journal:  J Ophthalmol       Date:  2014-11-13       Impact factor: 1.909

10.  Ocular Weakness in Myasthenia Gravis: Changes in Affected Muscles are a Distinct Clinical Feature.

Authors:  Robert H P de Meel; Wouter F Raadsheer; Erik W van Zwet; Martijn R Tannemaat; Jan J G M Verschuuren
Journal:  J Neuromuscul Dis       Date:  2019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.